The biomarkers established in the prediction of response to targeted therapy for non-squamous NSCLC are the receptor tyrosine kinases, EGFR, ALK, and ROS1, along with RET, MET, HER2, KRAS, BRAF, NTRK, and NRG1. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.